Clinical Fellowships
Supports U.S. academic institutions to train physicians in ATTR Amyloidosis through multidisciplinary clinical education and research fellowships.
Funder: Alnylam Pharmaceuticals
Due Dates (Anticipated): August 2026 (Clinical Fellowships, projected)
Funding Amounts: Up to $95,000 per institution for a one-year clinical fellowship; funds are for salary and benefits only.
Summary: Supports U.S. academic institutions to train physicians in ATTR Amyloidosis through multidisciplinary education and research.
Key Information: Forecasted opportunity—dates and details may change; check program page for updates.
Description
This program provides funding to support educational clinical fellowships at U.S. academic institutions focused on Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). The primary goal is to advance the training of physicians in the diagnosis, treatment, and research of ATTR Amyloidosis, fostering multidisciplinary collaboration to improve early recognition, optimize treatment pathways, and accelerate the translation of emerging science into high-quality, patient-centered care. Funding must be used exclusively for fellow salary and benefits; institutional overhead or indirect costs are not permitted.
